ASCO 2026: GI Oncology Abstracts to Look Forward To.

With the 2026 ASCO Annual Meeting just days away, Drs. Nicholas Hornstein, Timothy Brown, and Udhayvir Grewal sit down for a rapid-fire, "mouth-to-butt" preview of the most practice-altering abstracts hitting the floor in Chicago. Armed with top-line press releases and early data, the team highlights their top three high-stakes selections across the entire GI tract. Key previews include: The Upper GI Blockbusters (Tim’s Picks): Updated HORIZON-GEA data showing why HER2/PD-1 bispecific synergy doesn't care about baseline PD-L1 expression; a compliance deep-dive from the Matterhorn trial; and the arrival of IsaBrin (an EGFR/HER3 bispecific ADC) moving the needle in second-line squamous cell esophageal cancer. The Midgut & Plenary Hype (Udhayvir’s Picks): Front-row seats for RESOLUTE-302, the monumental plenary session showcasing deruxantrib doubling overall survival (13 months vs. 6.7 months) in second-line RAS-mutant pancreatic cancer. Plus, the PHITE-302 trial proving frontline pemigatinib works for FGFR2-rearranged cholangiocarcinoma despite notorious accrual challenges. Below-the-Belt Tech & Wild West De-escalation (Nick’s Picks): The highly anticipated late-breaking PUMP trial testing adjuvant hepatic artery infusion (HAI) pumps for colorectal liver metastases. Then, a massive look at China's Abstract 3502, confirming that MSI-High colorectal patients who hit a Complete Clinical Response can safely stop maintenance immunotherapy and maintain a 100% 3-year overall survival rate. The Sci-Fi Future: A look outside the box at the Archer trial in lung cancer—utilizing a prophylactic peptide vaccine to train the immune system to short-circuit targeted therapy resistance mutations before they occur. Chapters: (00:00) Welcome and ASCO Preview (00:46) Top Three Picks Setup (01:28) HORIZON GEA HER2 Triplet (03:55) Matterhorn DFLOT Completion (06:11) IsaBrin for ESCC Second Line (08:10) RESOLUTE-302 RAS Inhibitor (13:12) PHITE 302 Pemigatinib Frontline (20:10) PUMP Trial Hepatic Infusion (24:02) MSI-High CRC Stop PD-1 (29:15) Archer Vaccine vs Resistance (33:30) Closing Thoughts and Chicago   You can find us on X: Gut Onc Lab (@TheGutOncLab) / X